ArticleClinical medicine insights. Arthritis and musculoskeletal disorders2024
Role of Interleukin-17 in Predicting Activity of Rheumatoid Arthritis and Systemic Lupus Erythematosus.
Article in Clinical medicine insights. Arthritis and musculoskeletal disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Association of serum TNF-α, IL-17 A, and IL-17 F levels with disease activity in Yemeni patients with rheumatoid arthritis.Scientific reports · 2026Article
- Pathogenic and Clinical Relevance of Serum IL-17A and TNF-α in Systemic Lupus Erythematosus.International journal of molecular sciences · 2026Article
- Immune network dysregulation in rheumatoid arthritis and systemic lupus erythematosus: cytokine signatures, autoantibody profiles, and implications for precision medicine.Frontiers in medicine · 2026Article
- The Role of IL-17 in Periodontitis and Its Systemic Connections.International journal of molecular sciences · 2025Review
- The Effect of Vitamin D Supplementation on Clinical and Laboratory Biomarkers in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.Mediterranean journal of rheumatology · 2025Article
- Serum Interleukin-17 and Its Association with Inflammation and Bone Remodeling in Rheumatoid Arthritis and Hand Osteoarthritis: Insights from Musculoskeletal Ultrasound.Diagnostics (Basel, Switzerland) · 2025Article
- Photobiomodulation and the oral-gut microbiome axis: therapeutic potential and challenges.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although high serum levels of interleukin (IL)-17 and its producing cells have been found in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) in earlier research, it is still unclear how these findings relate to disease activity. Objectives: This study examines the link between serum levels of IL-17 and the activity of both RA and SLE. Design: This pilot case-control study included 100 patients with RA, 100 with SLE, and 100 healthy controls. Methods: The Disease Activity Score-28 (DAS28) scores assessed the activity of RA, whereas the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores assessed SLE activity. All participants' data were compared and correlated. Results: Serum levels of IL-17 were significantly higher in RA and SLE patients compared with the controls ( Conclusions: There is a significant correlation between RA and SLE activity and serum levels of IL-17. This discovery emphasizes IL-17 as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.